Oral Ketamine for Chronic Pain: Questions to Ask Before Trying It

If you are considering oral ketamine for persistent pain, the most useful question is not simply whether ketamine relieves pain. It is whether evidence supports the proposed oral treatment for your particular diagnosis and goals. Two reviews published in 2025 show why that distinction matters. One review examined randomized studies of oral ketamine as an analgesic.

First identify the kind of pain being discussed

A review in the Journal of Pharmacy Practice and Research included 21 studies, all involving oral ketamine, with one also comparing oral and sublingual administration. Most did not concern long-term chronic pain: 12 examined procedural pain, two examined postoperative pain, and five investigated chronic pain. Chronic pain results were heterogeneous, meaning they were not consistent across studies. Read the review’s study breakdown.

This is why a headline about pain relief needs a second look. Reducing pain during a procedure is not the same question as improving daily function over months. Ask whether the evidence being cited actually addresses the problem you are trying to solve.

Understand what a review can—and cannot—settle

The other 2025 review selected six randomized studies. Three comparisons with other analgesics found no between-group differences. Two placebo comparisons had different results: one found reduced local-anesthetic use and intraoperative pain, while another found no difference. The authors described evidence for selected patients with refractory chronic neuropathic pain as preliminary. The abstract reports the findings and conclusion.

Preliminary does not mean proven ineffective. It also does not mean established benefit. It means the uncertainty should remain visible in the treatment discussion, particularly when a provider is proposing repeated or ongoing treatment.

Ask about goals beyond a single pain score

Before starting, ask your clinician to define what would count as worthwhile improvement for you. You might choose to discuss a specific activity, the ability to complete a daily task, or another personally important goal alongside symptom ratings. Request a baseline record so later decisions are not based only on an overall impression.

Useful questions include how soon the plan will be reviewed, what information you should record, and whether any improvement needs to persist between doses. These are shared-decision questions, not a suggestion that one outcome measure is right for every patient.

Do not treat oral use as a safety guarantee

The six-study review reported common adverse reactions but noted that their severity was not reported. That limits what readers can conclude about tolerability from the included evidence. A convenient route of administration should not be confused with a well-established long-term safety profile. See the review’s safety reporting.

Ask which adverse effects the clinician expects to monitor, which symptoms require prompt contact, and how other medicines or substances will be reviewed. Request instructions specific to the prescribed product rather than borrowing guidance from a different ketamine formulation.

Separate pain evidence from depression approvals

Spravato’s 2025 label includes adult treatment-resistant depression and a separate depressive-symptom indication involving acute suicidal ideation or behavior. It does not list chronic pain as an indication. Its approval therefore is not evidence that an oral ketamine preparation is approved or effective for chronic pain. Check Spravato’s actual indications.

If a treatment discussion moves between depression and pain research, ask the clinician to explain which findings apply to which condition. Having both symptoms does not make every study interchangeable.

A checklist for an informed appointment

• What is my pain diagnosis, and which studies match it?
• Why is oral ketamine being considered now?
• What benefit are we hoping to achieve?
• What uncertainties should I understand?
• How will adverse effects and medication interactions be reviewed?
• When will we reassess, and what would lead us to stop?

A careful plan should make room for a result that is helpful, unhelpful, or too difficult to tolerate. Agreeing in advance on review points can make those conversations clearer and keep the treatment focused on your needs.

Talk with a qualified pain clinician before starting or changing treatment, and ask for advice tailored to your diagnosis, health history, and current medications.

Sources

• Journal of Pain & Palliative Care Pharmacotherapy: Oral ketamine systematic review
• Journal of Pharmacy Practice and Research: Oral and sublingual ketamine review
• FDA: Spravato prescribing information